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A B S T R A C T
High-risk human papillomaviruses (HR-HPV) infect basal keratinocytes, where in some individuals they evade
host immune responses and persist. Persistent HR-HPV infection of the cervix causes precancerous neoplasia that
can eventuate in cervical cancer. Dendritic cells (DCs) are eﬃcient in priming/cross-priming antigen-speciﬁc T
cells and generating antiviral and antitumor cytotoxic CD8+ T cells. However, HR-HPV have adopted various
immunosuppressive strategies, with modulation of DC function crucial to escape from the host adaptive immune
response. HPV E6 and E7 oncoproteins alter recruitment and localization of epidermal DCs, while soluble reg-
ulatory factors derived from HPV-induced hyperplastic epithelium change DC development and inﬂuence in-
itiation of speciﬁc cellular immune responses. This review focuses on current evidence for HR-HPV manipulation
of antigen presentation in dendritic cells and escape from host immunity.
1. Introduction
HPVs are epitheliotropic, double-stranded DNA viruses that infect
basal keratinocytes (KCs) on surface epithelia of skin and mucosal
membranes. Cervical and other anogenital cancers account for ~5% of
the global cancer burden [1,2] and are associated with infection of
‘high-risk’ HPVs; mainly HPV16 and HPV18. Together, HPV16 and 18
are responsible for ~70% of all cervical cancer cases worldwide, and
approximately ~60% of oropharyngeal cancers are associated with
HPV16 [2–7]. More than 200 HPV genotypes have been identiﬁed.
Mucosal HPVs are categorized based on their oncogenicity into high-
risk (HR) and low-risk (LR) types [8,9]. Persistence of HR-HPV infection
is the key step in the transformation of normal epithelium to pre-
cancerous and cancerous lesions [10,11]. The anogenital precancerous
lesions, otherwise known as intraepithelial neoplasia, e.g. cervical in-
traepithelial neoplasia (CIN), can be subcategorized into low-grade
(CIN1) and high-grade (CIN2/3) lesions. The development of HPV-re-
lated precancerous lesions, and cancer, is dependent on the expression
of HR-HPV E6 and E7 oncoproteins; E6 and E7 oncoproteins disrupt the
function of host cell cycle regulatory proteins in infected KCs and
trigger cell transformation. These two oncoproteins enact cell cycle
dysregulation via separate mechanisms. E6 binds to the host ubiquitin
ligase E6-associated protein (E6AP/UBE3A) and promotes degradation
of the p53 tumor suppressor gene product, a transcription factor pro-
moting DNA repair, cell cycle arrest and apoptosis. In contrast, HPV E7
binds to retinoblastoma (pRb) and displaces the transcription control
factor E2F, leading to constitutive expression of E2F-responsive genes,
promoting cell cycle activation [12–14].
The immune system plays a key role during HPV-associated carci-
nogenesis. About 90% of immunocompetent HPV-infected individuals
resolve a cervical infection spontaneously within three years and less
than 1% develop invasive cervical cancer [15]. Cell-mediated immunity
is considered to be crucial for clearance of HPV infections and HPV-
related malignancy is more prevalent in immunocompromised in-
dividuals [16,17]. The presence of a cytotoxic CD8+ T cell inﬁltrate in
HPV-related tumors corresponds with improved patient survival [5,18].
The entire HPV infection and life cycle of the virus is exclusively within
epidermal KCs. KCs themselves are considered as a component of the
innate immune system with immune sentinel functions [19,20]. They
express several toll-like receptors (TLRs) that recognize pathogen-as-
sociated molecular patterns (PAMPs) on pathogens, triggering produc-
tion of type I interferon (IFN), defensins and proinﬂammatory cytokines
such as interleukin 1 β (IL1-β) and tumor necrosis factor α (TNF-α)
[21,22].
2. Impact of HPV infection on KC susceptibility to immune
responses
In vitro transfection of primary KC with episomal HPV, or HPV gene
expression vectors, has demonstrated that HR-HPV gene products can
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prevent proinﬂammatory KC innate immune responses and suscept-
ibility of KC to immune mediated elimination. Expression of the E6 and
E7 genes of HR-HPV downregulates transcription and function of the
viral DNA sensor, TLR9 [23,24]. In addition, primary KCs transfected
with HPV16 and HPV18 episomes show disrupted expression of in-
ﬂammatory cytokine and chemokine genes [21]. HR-HPV E6/E7 on-
coproteins inhibit NFκB activation and TLR-mediated proinﬂammatory
cytokine and chemokine secretion, for proteins such as IFN-β, IL1-β, IL-
8, CCL2, CCL5, and MIP3α, thus limiting innate immune cell traﬃcking
and antigen (Ag)-speciﬁc eﬀector cell activation. The HR-HPV onco-
proteins inhibit NFκB signaling by blocking translocation of NFκB to the
nucleus [25,26], and suppressing NFκB nuclear transcriptional activ-
ities through enhancing interferon-related developmental regulator 1
(IFDR1) expression [27], and promote E6 dependent proteolytic de-
struction of IL-1β [28]. As a result, HPV-infected KCs fail to produce
type-I IFN and the proinﬂammatory cytokines, TNF-α, IL-6, IL-8 and
MIP3a [25,26]. HR-HPV infection of primary human KCs also prevents
IFN-γ-mediated cell-cycle arrest and blocks TNFα-mediated induction
of necroptosis by downregulating interferon-induced transmembrane
protein 1 (IFITM1) and receptor-interacting protein kinase 3 (RIPK3),
respectively [29]. The HPV16 E5 early gene product has been shown,
using immortalised HPV infected KCs, to downregulate expression of
class I major histocompatibility complex (MHC-I) molecules [30,31],
reducing susceptibility of KC to CD8 T cell-mediated killing. HPV16 E7
protein expression in KCs also impairs IFN-γ-mediated enhancement of
antigen (Ag) processing, presentation and cytotoxic T lymphocyte (C-
TL)-mediated lysis by impairing phosphorylation of STAT-1, resulting
in suppression of IRF-1 mediated upregulation of TAP-1 [32–34].
3. Impact of HPV infection on antigen presentation to the adaptive
immune system
To induce a cytotoxic T cell response against infected KCs, skin
resident antigen presenting cells (APCs) must initiate and coordinate
innate and adaptive immune responses. Skin resident professional APCs
tissue-resident macrophages and dendritic cells (DCs). DCs are the only
professional APCs that eﬃciently cross-present cell-associated Ags and
transport processed Ag to the draining lymph nodes (LNs) to activate
proliferation of naïve T cells [35,36]. Tissue-resident-macrophages are
major scavenger APCs responsible for phagocytosis of apoptotic cells
and maintenance of local homeostasis. However they do not speciﬁcally
migrate to the draining LNs and are less eﬃcient in Ag presentation to T
cells [36]. DCs are a highly heterogeneous group of APCs with func-
tionally distinct subsets. Human skin DCs comprise epidermal Langer-
hans cells (LCs), dermal conventional DCs (cDCs) and monocyte-de-
rived DCs, however, local inﬂammation is associated with a skin
inﬁltrate of plasmacytoid DCs, the main source of type I IFN during
viral infection [37,38]. Murine models have been useful for under-
standing the biological functions, and dysfunctions, of antigen pre-
senting cells in the skin under steady state and disease. It is important to
note that there are fundamental diﬀerences in cellular machinery be-
tween mouse and human skin. Most studies on mouse models utilized
haired skin where there is more densely packed hair follicles relative to
human skin, or in the cervix, are absent. The epidermal layers of mouse
and human skin are also diﬀerent in thickness [39]. However, mouse
skin and human skin contain similar immune cell types: Langerhans
cells and tissue resident memory CD8+ T cells in the epidermis, and
dermal DCs, macrophages, neutrophils, CD4+ T cells and ILCs in the
dermal compartment [38]. Mouse skin also contains additional cell
types such as dendritic epidermal T cells and gamma-delta T cells [40].
In healthy skin, LCs are the only resident DCs in the epidermis and
account for 3–5% of epidermal nucleated cells [41,42]. They originate
from embryonic precursors before birth and, in contrast to other DC
subsets, are radio-resistant. They continuously repopulate locally in the
basement membrane under the epidermal layer without the need for
continuous input from bone marrow precursors. Both human and
murine LCs can be identiﬁed through the expression of CD11b, epi-
thelial cell adhesion molecule (EpCAM) and langerin (CD207) [43,44].
Dermal cDCs arise from hematopoietic precursors and mainly comprise
murine CD11c+ CD11b+ and CD103+ DCs and their functionally
equivalent human CD1c+ and CD141+ DCs, respectively. Mouse and
human skin DCs, in both steady-state and inﬂammatory conditions,
capture and transport cutaneous Ag to draining LNs of the T cell zone
and initiate Ag-speciﬁc T cell responses [45–47]. The focus of the re-
mainder of this review is on the inﬂuence of HPV infection on Ag
presentation by professional APC in skin.
3.1. The eﬀects of HPV on dendritic cell frequency and distribution
Regulating DC diﬀerentiation and function is an essential me-
chanism for tumor escape from immune surveillance [48]. Several
studies have demonstrated that progression of HPV-induced carcino-
genesis is associated with alteration of frequency and distribution of
LCs, the epidermal DCs which normally reside where HPV infection
occurs [49]. HR-HPV positive cancer cells, and E6- and E7-expressing
cells can inhibit diﬀerentiation of monocytes into LCs in vitro [50]. In
cervical precancerous lesions and invasive cancers, active HR-HPV in-
fection and/or expression of E6/E7 oncoproteins were correlated with
depletion of intraepithelial LCs [51,52]. Similarly, the expression of
HPV16 E7 protein alone in murine epidermis has been associated with
signiﬁcantly reduced numbers of epidermal LCs [53]. Besides HR-HPV-
related lesions, in immunohistochemical studies of patient skin biop-
sies, the density of LCs was reduced in HPV8-positive Epidermodysplasia
Verruciformis patient skin lesions [54] and in chronic HPV-associated
skin warts APCs gradually disappeared from the epidermis with their
retention below the basement membrane of the epidermal layer [55].
Signiﬁcantly, accumulation of LCs in cervical biopsies is associated with
clearance of cervical HPV infection [56]. In addition, although the
number of intratumoral LC in head and neck squamous cell cancer
(HNSCC) patients was higher relative to precancerous lesions, HPV-
positive HNSCC patients contained a smaller number of intratumoral
LCs as compared to HPV-negative HNSCC patients and increase in LC
frequency has been correlated with recurrence-free survival [57]. Col-
lectively, these data suggest that epidermal-resident LCs might be im-
portant for control of HPV-induced lesions and inhibition of LC in-
ﬁltration to HPV-infected epidermis could be an immune escape
mechanism of the virus.
One mechanism that could produce the altered number and dis-
tribution of LCs may be the observed downregulation in HR-HPV-in-
fected KCs of the expression of the chemokines CCL20/MIP3α and E-
cadherin [58,59] in conjunction with inhibition of KC proinﬂammatory
and chemotactic cytokines response [25,26]. KCs play a signiﬁcant role
in the development and maintenance of epidermal LCs. KCs express
CCL20 that results in migration of immature LCs to the epidermis, while
E-cadherin expressed by KCs mediates adherence of LCs to KCs [60–62].
Under homeostatic conditions, IL-34 derived from KCs regulates the
local replenishment of LCs [63], while KCs help maintain LCs in the
epidermis via integrin-mediated activation of transforming growth
factor β (TGF-β). TGF-β, an autocrine LC transcriptional factor required
for its epidermal localization, is activated by integrin αvβ6 and αvβ8
derived from KCs [64]. Furthermore, in vitro experiments revealed that
the KC-to-LC interaction mediated by E-cadherin is required for LC
diﬀerentiation [65]. In HPV16-infected cervical epithelium, E6 and E7
expression and disease severity were correlated with downregulation of
CCL20 expression [52] and HPV16 E6 and E7 silencing in vitro pro-
motes CCL20 secretion and LC migration into HPV-infected epithelium
[66]. Moreover, in HPV-positive HNSCC patients, im-
munohistochemical proﬁling showed that reduced CCL20 expression is
correlated with a signiﬁcant decrease in LC inﬁltration into tumors
[57]. Most importantly, in vitro gene transfection studies in human
primary KCs have demonstrated that CCL20 expression is inhibited by
HPV viral proteins via downregulation of NF-κB signaling [58] and
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inhibition of binding of the cellular transcription factor CCAAT/en-
hancer binding protein (C/EBP) to a CCL20 promoter [67]. In this
study, C/EBP from normal KCs colocalized with and enhanced the ex-
pression of CCL20. However, human KCs transfected with HPV8 E7
protein exhibited decreased CCL20 expression by preventing binding of
C/EBP to the CCL20 promoter [67], suggesting a possible mechanism
for HPV oncoprotein interference with KC-derived CCL20, which at-
tracts LCs. Similarly, lower E-cadherin expression on HPV-infected KCs
is correlated with cervical lesion severity [59,68,69] and reduced
numbers of LCs in HPV-infected epidermis [60,70]. In vitro, inhibition
of HPV16 E6 and E7 oncoproteins restored E-cadherin expression and
LC adhesion to KCs [69,70]. Together, these data imply that recruit-
ment and localization of DCs to HPV-infected epithelia may hamper
accessibility of HPV proteins to APCs and this may in part contribute to
failure to generate eﬀective anti-HPV CTL responses.
3.2. The eﬀects of HPV on dendritic cells activation
DC functional maturation is instrumental in generating Ag-speciﬁc
immune responses. DCs continuously sample the peripheral tissues and
recognize pathogens or danger-signals from dying or infected cells and
undergo immunogenic maturation, characterized by transport of en-
dosomal MHC-II to the cell membrane, up-regulation of CD80 (B7-1)
and CD86 (B7-2) co-stimulatory molecules and secretion of instructive
proinﬂammatory cytokines, including IL-1α/β, IL-6, IL-12 and TNF-α,
and chemokines, including CCL2, CCL3, and CCR4 [71,72]. Mature DCs
present processed Ags in association with MHC molecules to naïve T
cells, and instruct T cell proliferation by providing co-stimulatory sig-
nals and cytokines which aid the diﬀerentiation of T cells [73,74].
However, several studies have demonstrated that HR-HPV infection
leads to impaired DC maturation, thus limiting their capacity to sti-
mulate a CTL response and this promotes lesion progression [51,75]. T
cells which encounter their cognate peptide on immature DCs that lack
the co-stimulatory surface markers and/or proinﬂammatory cytokines
are tolerized, a critical mechanism which the tumor uses to escape from
host immune attacks [76].
In the context of chronic HPV infection, in addition to the low
density of LCs, expression of MHC-ΙΙ and langerin on LCs in HR-HPV
positive cervical low-grade CIN1 lesions was signiﬁcantly reduced as
compared to the normal cervical epithelium [51]. Further, in patients
with HR-HPV-mediated CIN, downregulation of MHC and co-stimula-
tory molecules on cervical intraepithelial CD11c+ DC was signiﬁcantly
correlated with lesion severity [75]. An in vitro model using self-as-
sembled HPV viral-like particles (VLPs) was designed to study skin-re-
sident APC-mediated anti-HPV immune responses. In vitro exposure of
immature LCs isolated from CIN2/3 patients [77] or healthy volunteers
[78] to HPV16 L1L2 VLPs failed to up-regulate MHC and co-stimulatory
molecules and did not promote secretion of proinﬂammatory cytokines
and chemokines [77,78]. The in vitro suppressive eﬀect of VLPs is not
limited to HPV16, but exposure to many HR-HPV and LR-HPV VLPs also
inhibits activation of LCs [79]. In the absence of an inﬂammatory sti-
mulus, CD8+ T cells co-cultured with HPV VLP exposed LCs did not
proliferate or secrete the eﬀector cytokine IFN-γ [77,78]. On the other
hand, while exposure to HPV16 L1 major capsid VLP alone triggers
activation of human monocyte-derived LCs, HPV16 VLPs that contain
the minor capsid protein L2, individually or with L1 were unable to
induce LC activation [80]. However, human monocyte-derived DCs
incubated with either HPV16 L1 or L1L2 VLPs upregulated activation
molecules and were able to stimulate proliferation of T cells [80,81].
The minor capsid protein L2-mediated interaction of HPV16 with an-
nexin A2 heterotetramer (A2t) on LC is suggested as one possible me-
chanism for HPV-induced interference with LC maturation [82],
leading to a failure to generate speciﬁc cellular immune responses
during early HPV infection. This LC-speciﬁc inhibition by HPV L2 VLP
may indicate one HPV immune escape mechanism. However, full ma-
turation and Ag-speciﬁc CD8 T cell stimulatory capacity could be
achieved when HPV VLP exposed LC were also stimulated with TLR
agonists [77,79] or cell-derived cytokine-based biologic (IRX-2) con-
sisting of IL-1β, IL-2, IL-6, IL-8, TNF-α, GM-CSF, and IFN-γ [83], sug-
gesting that administration of local inﬂammatory stimuli restore HPV
capsid protein tolerized LC activation. Together, APC dysfunction
during HR-HPV infection appears to be associated with accumulation of
“immature” APCs, or depletion of mature DCs, in the local environ-
ment, which may consequently adversely impact on T cell priming in
the draining LNs and mounting of an appropriate immune response
against infected cells.
The eﬀect of HPV-induced malignancy has been modelled in a
murine skin grafting model where mice are engineered to express a
HPV16 E7 transgene within basal KCs under the control of keratin 14
(K14) transcriptional promoter (K14E7). K14E7 skin displays epithelial
hyperplasia that mimics HPV-related human CIN [84–86]. Similar to
LCs isolated from human cervical epithelium, epidermal LCs from
K14E7 transgenic mice exhibit low expression of MHC-ΙΙ and langerin/
CD207, but the levels of CD40, CD80 and CD86 surface molecules were
up-regulated as compared to non-transgenic mouse skin [87,88]. De-
spite their partially activated state, in vivo Ag-processing and T cell
priming capacity of K14E7 skin DCs was impaired [88]. Further, LCs in
K14E7 epidermis showed a regulatory phenotype characterized by ex-
pression of indoleamine 2, 3-dioxygenase 1(IDO-1) and arginase 1 (Arg-
1) [88,89]. However, in murine epidermis transduced with HPV16 E7,
depletion of LCs had no eﬀect on suppression of CTL responses by
HPV16 E7 [53]. In a murine contact hypersensitivity model, activation
of skin eﬀector T cells required antigen presentation by dermal DCs, but
not LCs [90]. Therefore, whether the dysregulation of epidermal LCs is
relevant to failure to initiate HPV-speciﬁc CD8+ T cell responses re-
quires further investigation.
4. Chronic HPV infection, immunoregulatory cytokine milieu and
DCs
4.1. Immunoregulatory soluble factors
As indicated in Fig. 1 and Table 1, local immunosuppressive sig-
naling established during precancerous epithelial neoplasia seems to
play a signiﬁcant role in HPV-related carcinogenesis, possibly through
modulating APC activation and function. HPV-transformed cells pro-
duce immunoregulatory soluble factors and recruit suppressive cells,
tumor-associated macrophages, myeloid-derived suppressor cells and
regulatory T (Treg) cells, which instruct tolerogenic DC diﬀerentiation
and promote lesion progression [91,92]. HPV-transformed cell lines
and tissues studied from patients with cervical cancer and high-grade
CINs have demonstrated that the soluble mediators, IL-10, TGF-β and
prostaglandins (PG), play a key role in the establishment of an im-
munosuppressive milieu [93–96]. PGE2 produced by HPV-driven ma-
lignant epithelium inhibits DC maturation and Ag presentation [97]. In
the HPV-associated neoplastic epithelium, accumulation of TGF-β and
IL-10, chief regulator of DC development and function, was correlated
with disease severity [92,98]. IL-10 secreted from Treg cells down-
regulated maturation of DCs by up-regulating the E3 ubiquitin ligase
MARCH-I expression, which increased ubiquitination and degradation
of MHC and costimulatory molecule [99]. The possible DC suppressive
eﬀect of IL-10 and TGF-β in a chronic HPV-infected local micro-
environment is evidenced by a correlation between elevated levels of
TGF-β and IL-10 positive Treg cells, regulatory DCs and impaired CTL
responses in cervical cancer epithelium compared to normal cervix
[95]. This was also seen in mouse models where HPV Ag-experienced
experimental mice produced IFN-γ, favouring the generation of IL-10+
CD4+ T cells and impaired CTL responses [100]. Additionally, in vitro
examination of HPV-positive cervical cancer cell lines demonstrated
that IL-10 and TGF-β derived from cancer cells suppress MHC-I ex-
pression in tumor cells [101], preventing CTL-mediated clearance of
HPV-transformed KCs. Moreover, the expression of co-stimulatory and
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MHC-II in DCs co-cultured with genital squamous cell carcinoma (SCC)
cell lines was signiﬁcantly reduced via a receptor activator of nuclear
factor kappa-B ligand (RANKL) cytokine-mediated eﬀect although cells
retained their ability to up-regulate lymphoid homing receptor CCR7,
thereby inducing tolerogenic DC development [102]. The chemokine
receptor CCR7 is expressed by mature DCs and plays a role in mediating
DC traﬃcking in response to LN homing CCL19 and CCL21 chemokines
[103]. Upregulated expression of CCR7 on DCs within HPV-infected
squamous epithelium and with a low level of co-stimulatory markers
may induce migration of immunologically inactive DCs to draining LNs
[104]. In addition, HR-HPV-positive cervical cancer cell lines induced
monocyte recruitment and diﬀerentiation to immature DCs in vitro.
However, the migration of mature DCs was impaired by cervical cancer
cell-derived IL-6, which led to suppression of CCR7 [105].
Antigen-experienced Treg cells modulate the maturation of DCs via
cytotoxic T lymphocyte-antigen-4 (CTLA-4)-mediated down-regulation
of CD80 and CD86 expression. CTLA-4 binds to CD80 and CD86 with
higher aﬃnity than CD28, and Treg cell interaction with DCs via CTLA-4
downregulates CD80 and CD86 expression, thus limiting the ability of
DCs to stimulate CD8+ T cells [106]. The expression of CTLA-4, the
immune checkpoint receptor, on Treg cells provides an important
strategy for diﬀerent tumor cells to evade host immune surveillance.
Accumulation of CTLA-4+ Treg cells in the HPV-positive HNSCC tumor
microenvironment [107] and in the peripheral blood of advanced cer-
vical cancer [108] patients, suggests a repressive role for CTLA-4 during
HPV infection. The clinical beneﬁts of blocking the CTLA-4 immune
inhibitory pathway is also under clinical evaluation in cervical cancer
[109] and HNSCC patients [110].
HPV16 E7-expressing mouse premalignant skin has also shown
suppressed immune responses. Unlike skin expressing mOVA from an
epidermal keratin 5 (K5) promoter- [111] or K14-driven human growth
hormone (K14hGH) neo-self-antigens [112], E7-expressing murine skin
is not rejected when engrafted onto immunocompetent syngeneic, non-
transgenic recipient hosts [86], and an E7 immunization induced
CD8+ T cell response, was not suﬃcient to enable graft rejection
[113]. Administration of Listeria monocytogenes or bacterial endotoxin
at the time of grafting of E7 transgenic skin promoted graft rejection
[114]. This suggests that local application of proinﬂammatory stimuli
may overcome a suppressive environment by sustaining stimulatory
signals that help rescue immunogenic DC activation [115]. However,
although CD4+CD25+ T cell depletion increased Ag-speciﬁc CD8 T
cell responses in E7- expressing mice [116], these were insuﬃcient to
induce graft rejection [117]. Natural killer T (NKT) cells inhibit rejec-
tion of E7-grafts, and DCs isolated from NKT cell deﬁcient mice re-
cipient of E7 skin grafts have shown enhanced Ag-speciﬁc T cell sti-
mulatory function in draining LNs [117]. Invariant NKT cell interaction
with immature DCs can program maturation of tolerogenic DC [118]
expressing immunoregulatory molecules including IDO. An increased
NKT cell inﬁltration with increased levels of IFN-γ expression has also
been observed in cervical tissues of patients with high-grade (CIN2/3)
lesions [119], although the protective or suppressive nature of this
response is unknown. Altogether, immune inﬁltrates into the tumor
microenvironment may suppress anti-HPV responses by promoting
regulatory DC development, thus inducing expansion of ineﬀective
tumor inﬁltrating CD8+ T cells.
4.2. Indoleamine 2, 3-dioxygenase
Prolonged local IFN-γ-signaling contributes to E7-induced im-
munosuppression in K14E7 animals, as IFN-γ-deﬁcient K14E7 skin
grafts were spontaneously rejected by non-transgenic
Fig. 1. Schematic illustration of tumor -inﬁltrating T cell interactions with dendritic cells.
Chronic IFN-γ secretion from tumor inﬁltrating cells and cell to cell interaction through
CTLA-4 on Treg cells with CD80/CD86 on DCs induce IDO expression and activities. The
increased activity of IDO inhibits eﬀector function of T cells through depleting tryptophan
and increased kynurenine catabolite, kynurenine. Increase production of the immune
inhibitory molecules IL-10, TGF-β and CTLA-4 in Treg cells downregulate maturation of
DCs. Ligation of TCR with cognate peptide-loaded MHC molecules on dendritic cells that
lack the co-stimulatory surface markers and/or PD-1-PD-L1 interactions lead to T cell
proliferation arrest or anergy. APC: antigen presenting cell; IDO-1: Indoleamine 2, 3-
dioxygenase; IL-10: interlunkin-10; IFN-γ: Interferon γ; IFN-γ-R: IFN-γ receptor; CTLA-4:
cytotoxic lymphocyte-associated antigen-4; TCR: T cell receptor; PD-1/PD-L1: pro-
grammed death receptor 1/programmed death ligand 1; TGF-β: Tumor growth factor β.
Table 1
Summary of some of the common regulatory mediators in HR-HPV- induced malignancies.
Immunoregulatory factors Main source Mechanisms of immune regulation Possible eﬀect Reference
Arg-1 DCs and other myeloid cells • Depletion of arginine • Inhibit T cells proliferation and
function
[88]
TGF-β& IL-10 Tumor cells, TAM, Treg
cells, DCs
• Modulate DC maturation• ↓Overall immune activation •
↑Treg cell and regulatory DC
diﬀerentiation
• ↓Lymphocyte functions
[91,93–96]
IFN-γ Activated T cells • ↑IDO and PD-L production • ↑Treg function• ↓T cell eﬀector function
[88,89,95]
PD-L1 Tumor cells, APCs • Delivers inhibitory signal to T cells via PD1
receptor molecules
• ↓T cell activation and proliferation [75,93,130]
PD-1 T cells • Delivers intracellular negative signal • Induce T cell anergy or exhaustion [93,132]
CTLA-4 T cells • Competitively inhibit CD80 and CD86 co-
stimulatory functions
• Induce IDO production
• ↓T cell eﬀector function [107,108,110]
IDO-1 Tumor cells, DCs • Depletion of tryptophan• ↑ toxic tryptophan metabolites •
↑T cell apoptosis
• ↓T cell eﬀector function
[88,89,122–124]
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immunocompetent hosts [117]. IFN-γ exhibits anti-inﬂammatory and
immunomodulatory functions and is the primary inducer of in-
doleamine 2, 3-dioxygenase (IDO) production from various cell types,
including APCs and tumor cells [120]. IDO is an immunoregulatory
enzyme that breaks down L-tryptophan, an important amino acid re-
quired for T cell eﬀector function, to the immune inhibitory metabolite
called kynurenine. Increased activity of IDO leads to local depletion of
tryptophan and an increase in kynurenine, which subsequently inhibits
the immune response by inducing apoptosis of eﬀector T cells, con-
verting naïve T cells into Treg cells or leading to cell cycle arrest
[120,121].
In a cervical cancer patient biopsy analysis, IDO1 gene expression
and kynurenine to tryptophan ratio was signiﬁcantly elevated as com-
pared to healthy controls [122]. Increased expression and activities of
serum IDO [123] and cervical tumor cell IDO expression [124] were
negatively associated with survival of cervical cancer patients. Mark-
edly higher inﬁltration of stromal immature IDO+ DCs were observed
from cervical tissues of high-grade cervical neoplastic disease and
cancer [95]. Although the number of IFN-γ+ cells were lower in pa-
tients with cervical cancer compared to CIN, IFN-γ+ cells were sig-
niﬁcantly higher in high-grade CIN compared to normal cervix biopsies
[95]. Indeed, IFN-γ promotes antitumor immune responses and IFN-γ
producing eﬀector T cells are important positive predictors of improved
HPV-related cancer patient survival [125,126]. However, the number
of T cell populations within HPV-positive high grade CINs may not be
diﬀerent [119]. Further, despite the eﬀector role of IFN-γ in antitumor
immune response, there is increasing evidence that chronic IFN-γ re-
lease could promote immune suppression by upregulation of im-
munomodulatory signals such as PD-L1 and IDO in HPV-positive pre-
cancerous lesions [127]. Adding to the complexity of the role of IFN-γ,
IFN-γ can be produced by a variety of cells, which, in combination with
diﬀerent tissue microenvironments, can cause diﬀerent outcomes to the
immune response. One source of IFN-γ is from increased numbers of
invariant NKT cells, as seen in HPV-positive high-grade CIN compared
to HPV-positive low-grade CINs and HPV-negative cervical tissues
[119]. Invariant NKT cells and IFN-γ-dependent upregulated expression
and activity of IDO-1 were detected in the K14E7 murine skin DCs and
blockade of IDO-1 activities with 1-methyltryptophan (1-MT) led to
rejection of E7 transgenic skin grafts [88,89]. Additionally, in an ex-
perimental murine model of subcutaneously inoculated cervical tumor
cells, though in vitro tumor cell growth was not aﬀected, inhibition of
IDO activity promotes signiﬁcant intratumoral accumulation of natural
killer (NK) cells and regression of tumor growth [128]. Collectively
these data strongly suggest that prolonged or chronic IFN-γ signaling
might be responsible for IDO-1 expression by HPV-infected tissue DCs
and dysfunction of T cell response can be attributed to IFN-γ-induced
diﬀerentiation of regulatory DCs.
4.3. Programmed death ligand inhibitory signaling
DCs exposed to the HR-HPV-induced tumor microenvironment may
attenuate eﬀector T cell functions through programmed death receptor
1 (PD-1)/programmed death ligand 1(PD-1/PD-L1) immune inhibitory
signaling [75]. Normally, the inhibitory signaling is important to ter-
minate cell-mediated immune responses and is responsible for pre-
venting adverse immune reactions, such as immune-mediated destruc-
tion of normal cells during infections. The interaction between PD-1 on
T cells and its ligands PD-L1 (B7-H1) and PD-L2 (B7-DC) on APCs or
tumor cells delivers a negative signal that results in apoptosis and an-
ergy or exhaustion of T cells [106]. Aberrantly high PD-1/PD-L1 sig-
naling is associated with immune escape in cancer and HIV infection
[106,129]. K14E7 transgenic mouse skin DCs do not demonstrate ele-
vated expression of PD-L1 [88]. However, a correlation of increased PD-
1/PD-L1 expression and tumor -inﬁltrating T cell immune dysfunction
during HR-HPV-induced carcinogenesis of both cervical [75,93,130]
and oropharyngeal [131,132] cancer patients has been reported.
Likewise, there is signiﬁcantly elevated expression of PD-1 on T cells
and PD-L1 on DCs in cervical tissues [75,93] and draining LNs [133]
from patients with high-grade CIN, as compared to low-grade CIN and
CIN-negative patients. Furthermore, inﬁltration of functionally im-
paired PD-1+ CD8+ T cells is observed in HNSCC [132] and cervical
cancer [93] patients. In HPV-infected tissue, PD-L1-expressing DCs
have shown regulatory phenotypes, characterized by reduced co-sti-
mulatory molecule expression and IL-12 cytokine production, but up-
regulated secretion of IL-10 [75]. Interaction between DCs and T cells
via ligation of PD-L1/PD-1 and immunoregulatory cytokine secretion
may allow for immune escape during chronic HR-HPV infection. Im-
mune checkpoint blockade therapy can promote tumor clearance by the
host immune system. In vitro studies involving human cell lines ex-
pressing HPV16 E7 Ags have shown that blockade of PD-1/PD-L1 sig-
naling signiﬁcantly enhanced CTL responses [93,130]. Pre-clinical
studies have also demonstrated that the combination of HPV16 E7
DNA-based therapeutic vaccines with co-blockade of PD-1/PD-L1 sig-
naling in E6- and E7-expressing transplantable TC-1 tumor bearing
mice can signiﬁcantly enhance the tumor -speciﬁc CTL response and
improve tumor regression [134–136]. Currently, there are several
clinical trials targeting blockade of PD-1/PD-L1 in HNSCCs and nivo-
lumab (anti-PD1 antibody) has been approved by the FDA for the
treatment of recurrent or metastatic HNSCC patients [110,137]. How-
ever, although pembrolizumab [138] and nivolumab [139] anti-PD-1
monoclonal antibodies are under phase I/II trials for the treatment of
cervical and other anogenital cancers, it remains to be determined if
these strategies can oﬀer a therapeutic advantage for clearance of HPV-
related tumors in patients.
5. Conclusion
HPV utilizes multiple strategies to evade host immune responses.
HR-HPV- infected KCs escape from CTL recognition through down-
regulation of MHC-I molecules and the associated Ag-processing ma-
chinery. Subverting the KC’s inﬂammatory response by HR-HPV E6 and
E7 non-structural oncoproteins contributes to the ineﬀectiveness of the
host immune response, thus promoting persistent HPV infection and KC
transformation. HPV E6 and E7 aﬀect epidermal recruitment and lo-
calization of LCs through disrupting KC-to-LC networks. The various
cell types recruited to HR-HPV infected lesions appear to interact with
resident (or recruited) APCs, setting up a feed-forward loop of im-
munoregulation to favour persistence of infected cells. In both pre-
clinical animal models and cervical cancer patients, HPV-related epi-
thelial dysplasia is associated with inﬁltration of immature DCs with
reduced ability to present Ags and stimulate T cell proliferation. Most
strikingly, within HR-HPV-infected or E6/E7-expressing hyperproli-
ferative epithelia, DCs exhibit regulatory phenotypes associated with
production of IL-10, IDO-1, and PD-L1. Persistent immunosuppressive
signaling through chronic IFN-γ, IL-10, and TGF-β in the HR-HPV-in-
fected hyperproliferative lesion is presumably responsible for recruiting
and programming tolerogenic DCs. Multiple clinical trials targeting
blockade of PD-1/PD-L1 and CTLA-4 immune checkpoints are being
conducted and may provide crucial help in diminishing the burden of
HPV- associated diseases. However, it is not yet clear whether HR-HPV-
induced malignancies directly suppress the CTL response or DCs con-
ditioned by the regulatory milieu actively divert T cell responses to-
wards tolerance. Thus, further investigation of the interaction between
APCs and tumor -derived soluble mediators within HPV-induced ma-
lignant epithelia may help with targeting DCs for therapeutic inter-
vention.
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